Olayemi Osiyemi

3.9k total citations
37 papers, 879 citations indexed

About

Olayemi Osiyemi is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Olayemi Osiyemi has authored 37 papers receiving a total of 879 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Infectious Diseases, 22 papers in Virology and 7 papers in Emergency Medicine. Recurrent topics in Olayemi Osiyemi's work include HIV/AIDS drug development and treatment (30 papers), HIV Research and Treatment (22 papers) and HIV/AIDS Research and Interventions (16 papers). Olayemi Osiyemi is often cited by papers focused on HIV/AIDS drug development and treatment (30 papers), HIV Research and Treatment (22 papers) and HIV/AIDS Research and Interventions (16 papers). Olayemi Osiyemi collaborates with scholars based in United States, Belgium and United Kingdom. Olayemi Osiyemi's co-authors include Brian Wynne, Jean van Wyk, Faïza Ajana, Mounir Ait‐Khaled, Keith A. Pappa, Ruolan Wang, Fiona Bisshop, Michael Aboud, Christoph Wyen and Jonathan Wright and has published in prestigious journals such as PLoS ONE, Clinical Infectious Diseases and The Journal of Infectious Diseases.

In The Last Decade

Olayemi Osiyemi

34 papers receiving 858 citations

Peers

Countries citing papers authored by Olayemi Osiyemi

Since Specialization

Citations

This map shows the geographic impact of Olayemi Osiyemi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olayemi Osiyemi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olayemi Osiyemi more than expected).

Fields of papers citing papers by Olayemi Osiyemi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olayemi Osiyemi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olayemi Osiyemi. The network helps show where Olayemi Osiyemi may publish in the future.

Co-authorship network of co-authors of Olayemi Osiyemi

This figure shows the co-authorship network connecting the top 25 collaborators of Olayemi Osiyemi. A scholar is included among the top collaborators of Olayemi Osiyemi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olayemi Osiyemi. Olayemi Osiyemi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Lenacapavir Plus 2 Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or Zinlirvimab 2025 ·The Journal of Infectious Diseases ·Joseph J. Eron, Paul Cook, Megha Mehrotra, Hailin Huang, Marina Caskey, (unknown), Linda Gorgos, Laurie A. VanderVeen, (unknown), Sean E Collins, Olayemi Osiyemi, Cynthia Brinson, Edwin DeJesus	1
2	Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial 2024 ·The Lancet HIV ·Anthony Mills, Giuliano Rizzardini, Moti Ramgopal, Olayemi Osiyemi, Johannes R. Bogner, Debbie Hagins, Roger Paredes, Jacques Reynes, Jürgen K. Rockstroh, Andrew Carr, (unknown), Stephanie O. Klopfer, Karen Eves, Rebeca M. Plank, (unknown), Michelle C. Fox	8
3	Bictegravir/emtricitabine/tenofovir alafenamide in adults with HIV‐1 and end‐stage kidney disease on chronic haemodialysis 2024 ·HIV Medicine ·Joseph J. Eron, Moti Ramgopal, Olayemi Osiyemi, Mehri S. McKellar, Jihad Slim, Edwin DeJesus, Priyanka Arora, Christiana Blair, Jason T. Hindman, Aimee Wilkin	0
4	Switching to dolutegravir/lamivudine (DTG/3TC) fixed-dose combination (FDC) is non-inferior to continuing a tenofovir alafenamide (TAF)-based regimen (TBR) in maintaining virological suppression through 96 weeks (TANGO study) 2021 ·HIV Medicine ·Jean van Wyk, F. Ajana, Fiona Bisshop, Christoph Stephan, Olayemi Osiyemi, Joaquín Portilla, Jean‐Pierre Routy, Christoph Wyen, Mounir Ait‐Khaled, (unknown), Keith A. Pappa, (unknown), (unknown), Brian Wynne, Michael Aboud, Kimberly Y. Smith	0
5	Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV 2021 ·AIDS ·Lerato Mohapi, (unknown), Olayemi Osiyemi, Khuanchai Supparatpinyo, Winai Ratanasuwan, Jean‐Michel Molina, Ron Dagan, Gretchen Tamms, Tina M. Sterling, Ying Zhang, Alison Pedley, (unknown), Yanqing Kan, (unknown), Luwy Musey, Jakub K. Simon, Ulrike K. Buchwald	19
6	1046. Week 48 Outcomes from the BRAAVE 2020 Study: A Randomized Switch to B/F/TAF in African American Adults with HIV 2020 ·Open Forum Infectious Diseases ·Debbie Hagins, Princy Kumar, Michael S. Saag, (unknown), Indira Brar, Daniel Berger, Olayemi Osiyemi, Corrilynn O. Hileman, Moti Ramgopal, Cheryl McDonald, Christiana Blair, Kristen Andreatta, Sean E Collins, Diana M. Brainard, Hal Martin	1
7	1002. A Daily Single Tablet Regimen (STR) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically-Suppressed Adults Living with HIV and End Stage Renal Disease on Chronic Hemodialysis 2020 ·Open Forum Infectious Diseases ·Joseph J. Eron, Aimee Wilkin, Moti Ramgopal, Olayemi Osiyemi, Mehri S. McKellar, (unknown), Jihad Slim, David M. Asmuth, Edwin DeJesus, Polina German, Christiana Blair, Christoph C Carter, Diana M. Brainard, Sean E Collins, Hal Martin	6
8	Reduced exposure to darunavir and cobicistat in HIV‐1‐infected pregnant women receiving a darunavir/cobicistat‐based regimen 2019 ·HIV Medicine ·(unknown), Olayemi Osiyemi, C. Zorrilla, (unknown), Kimberley Brown	19
9	Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96‐week results from two randomized clinical trials 2018 ·HIV Medicine ·(unknown), Chloe Orkin, (unknown), Anthony Mills, Cynthia Brinson, E DeJesus, Frank A. Post, (unknown), Melanie Thompson, Olayemi Osiyemi, Bruce Rashbaum, (unknown), Claudia Martorell, (unknown), (unknown), Danielle Porter, (unknown), Devi SenGupta, Manika Das	42
10	Pharmacokinetics, Antiviral Activity, and Safety of Rilpivirine in Pregnant Women with HIV-1 Infection: Results of a Phase 3b, Multicenter, Open-Label Study 2018 ·Infectious Diseases and Therapy ·Olayemi Osiyemi, Salih Yasin, Carmen Zorrilla, (unknown), (unknown), Kimberley Brown, Herta Crauwels	18
11	Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial 2016 ·The Lancet HIV ·Joel E. Gallant, Eric S. Daar, François Raffi, Cynthia Brinson, Peter Ruane, Edwin DeJesus, Margaret Johnson, Nathan Clumeck, Olayemi Osiyemi, (unknown), Javier O Morales-Ramirez, Mingjin Yan, Michael E. Abram, Andrew Plummer, Andrew Cheng, Martin S. Rhee	127
12	Brief Report 2015 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Jan van Lunzen, Anton Pozniak, José M. Gatell, Andrea Antinori, (unknown), Oscar K. Serrano, (unknown), Olayemi Osiyemi, (unknown), Pierre‐Marie Girard	16
13	Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial 2015 ·The Lancet HIV ·Samir K. Gupta, Grace A. McComsey, (unknown), Juan Echevarría, Catherine Orrell, Anchalee Avihingsanon, Olayemi Osiyemi, (unknown), Neelanjana Ray, David Stock, Samit R. Joshi, George J. Hanna, Max Lataillade	9
14	Antibiotic Susceptibilities of Bacteria Isolated within the Oral Flora of Florida Blacktip Sharks: Guidance for Empiric Antibiotic Therapy 2014 ·PLoS ONE ·(unknown), Erich Ritter, (unknown), Jay S. Goodman, Olayemi Osiyemi	15
15	Forty‐eight‐week efficacy and safety and early CNS tolerability of doravirine (MK‐1439), a novel NNRTI, with TDF/FTC in ART‐naive HIV‐positive patients 2014 ·Journal of the International AIDS Society ·Josep M. Gatell, (unknown), Debbie Hagins, Melanie Thompson, Keikawus Arastéh, Christian Hoffmann, Sorin Rugină, Olayemi Osiyemi, (unknown), Robin Dretler, (unknown), Xia Xu, Hedy Teppler	45
16	Clinical and Pharmacogenetic Factors Affecting Neonatal Bilirubinemia Following Atazanavir Treatment of Mothers During Pregnancy 2013 ·AIDS Research and Human Retroviruses ·Timothy Eley, Shu‐Pang Huang, Francesca Conradie, Carmen Zorrilla, (unknown), Mariëtte E. Botes, Olayemi Osiyemi, Hélène Hardy, Richard Bertz, Donnie McGrath	4
17	Effects of Darunavir/Ritonavir-Based Therapy on Metabolic and Anthropometric Parameters in Women and Men Over 48 Weeks 2011 ·AIDS Patient Care and STDs ·Judith S. Currier, Claudia Martorell, Olayemi Osiyemi, Michael T. Yin, Robert J. Ryan, Guy De La Rosa, Joseph Mrus	11
18	Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women 2011 ·HIV Medicine ·Francesca Conradie, C. Zorrilla, (unknown), (unknown), Olayemi Osiyemi, (unknown), Timothy Eley, Michael Child, Richard Bertz, (unknown), Victoria Wirtz, (unknown)	50
19	O413 Pharmacokinetics (PK) of once-daily etravirine (ETR) without and with once-daily darunavir/ritonavir (DRV/r) in antiretroviral-naïve HIV-1 infected adults 2008 ·Journal of the International AIDS Society ·Jacob Lalezari, E DeJesus, Olayemi Osiyemi, Peter Ruane, (unknown), Robert J. Ryan, (unknown), Thomas N. Kakuda, James Witek	6
20	CEREBRAL PHAEOHYPHOMYCOSIS DUE TO A NOVEL SPECIES: REPORT OF A CASE AND REVIEW OF THE LITERATURE 2001 ·Transplantation ·Olayemi Osiyemi, Lorraine Dowdy, (unknown), Timothy J. Cleary	32

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact